ascopubs.org

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth ...

Patients without baseline CNS metastases were randomly assigned (1:1) to receive lapatinib-capecitabine (lapatinib 1,250 mg per day; capecitabine 2,000 mg/m 2 per day on days 1 to 14 every 21 days) or ...
ascopubs.org

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer

Cohorts of three patients with ErbB2-positive advanced breast cancer were treated with escalating doses of lapatinib (750 to 1,500 mg) administered once daily (continuous) in combination with ...
National Institute for Health and Care Excellence

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination

After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on lapatinib or trastuzumab in combination with an aromatase inhibitor for ...
FiercePharma

NICE publishes appeal decision on lapatinib

The National Institute for Health and Clinical Excellence (NICE) has today (14 October) published the outcome of an appeal hearing relating to its draft guidance on the use of lapatinib (Tyverb, ...